subscribe Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Subscribe now

Roche agreed to take over unlisted obesity drug developer Carmot Therapeutics for $2.7bn upfront, joining a list of contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk and Eli Lilly.

The US takeover target’s most promising drug candidate, a once-a-week injection called CT-388, is a dual GLP-1/GIP receptor agonist such as Lilly’s Mounjaro, or Zepbound.

After encouraging phase I trial results, the Carmot drug is ready to be tested on humans in the second of three trial stages, with a possible market launch in the 2030s, Roche pharmaceuticals division head Teresa Graham said on Monday.

Weight-loss drug market leader Novo is ahead with its injection Wegovy, a single agonist of the GLP-1 gut hormone receptor. Overwhelming demand has left the group scrambling to boost production.

Roche’s share price rose 2.4% in morning trade on optimism that the weight-loss market, estimated by some analysts to reach as much as $100bn, will accommodate many rivals.

“The markets are large enough for ‘me too’ products, particularly when offered at the right price,” Zuercher Kantonalbank analysts said in a note.

Graham said the company wanted more than a low-price alternative to the leaders in the market, telling Reuters that CT-388 could become the best obesity drug in the GLP-1 class, on its own or used with other compounds.

“There is opportunity for deeper weight loss, there is opportunity for that weight loss to happen more quickly and tolerability is maybe one of the bigger issues,” said Graham.

Among recent deals to acquire obesity drug development projects, AstraZeneca last month agreed to pay up to $2bn for the rights to an experimental pill from China’s Eccogene. Lilly in July acquired unlisted Versanis for up to $1.93bn to further boost its pipeline.

New Roche CEO Thomas Schinecker, who is pursuing a variety of therapeutic fields to offset falling oncology sales, has set a high deal pace to restore the development pipeline that was hit by trial setbacks in Alzheimer’s and cancer immunotherapy last year.

Roche agreed in October to pay an initial $7.1bn to Roivant and Pfizer for rights to a new inflammatory bowel disease drug.

Under the Carmot deal, which is expected to close in the first quarter of 2024, its owners will receive up to $400m in addition to the upfront payment if certain milestones are achieved, Roche said.

For the Swiss drugmaker, the deal marks a return to a GLP-1 field that it abandoned in 2018, when its subsidiary Chugai sold the rights to an experimental pill to Lilly for $50m upfront.

“This is a place where we needed the science to evolve a bit more completely,” said Graham.

Privately held Carmot, which announced plans to go public last month, was cofounded in 2008 by long-time CEO Stig Hansen.

While keeping a Carmot board seat, Hansen early this year became CEO of Kimia Therapeutics, which was spun out of Carmot to focus on the discovery of new metabolic diseases drugs.

Carmot’s portfolio includes a range of gut-hormone drug candidates, in pill and injection form, aimed at treating obesity in patients with and without diabetes, said Roche.


subscribe Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Subscribe now

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.